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LETTERS TO THE EDITOR
Coronary Stenting or Percutaneous
Transluminal Coronary Angioplasty Prior to
Noncardiac Surgery Increases Adverse
Perioperative Cardiac Events: The Evidence
Is Mounting
The findings of Kalusa et al. (1) support previous evidence that
coronary manipulation ,90 days before noncardiac surgery (NCS)
does not benefit, and may actually harm, patients with coronary
disease. In 1997, the American College of Physicians concluded
that prophylactic coronary revascularization before NCS had not
been shown to decrease short-term mortality (2). They stated that
the need for revascularization in such patients should be deter-
mined on the same clinical grounds as it would be if they were not
undergoing NCS, and that without such indications, patients
should proceed directly to surgery. Based on lack of reasonable data
supporting preoperative angioplasty, they made similar recommen-
dations regarding prophylactic percutaneous transluminal coronary
angioplasty (PTCA), echoing previously published findings of the
American College of Cardiology (3).
We retrospectively studied 686 patients who underwent PTCA
before NCS, 686 matched surgery patients with uncorrected
coronary artery disease (CAD) and 2,155 matched normal control
subjects (4). Patients undergoing PTCA had twice the rate of
adverse cardiac outcomes as normal subjects, seven times the rate
of angina, almost four times the rate of myocardial infarction (MI)
and twice the rate of congestive heart failure (CHF). Twenty-six
percent of the patients who underwent PTCA ,90 days before
NCS had adverse cardiac outcomes. The odds ratio of adverse
cardiac outcome, angina, CHF and MI in patients with PTCA
,90 days before NCS, compared to normal subjects, were 2.8,
26.0, 2.4 and 34.0, respectively. Patients who underwent PTCA
within 90 days of NCS suffered twice the rate of perioperative MI
compared with patients with uncorrected CAD. Mason et al. (5)
and Fleisher et al. (6) found that patients with CAD undergoing
vascular surgery without coronary intervention had better out-
comes than patients who were revascularized. For nonvascular
surgery patients, the risk-to-benefit ratio of coronary revascular-
ization is probably even poorer than these studies suggest, due to
lower baseline risks of adverse cardiac outcomes.
Elmore et al. (7) and Huber et al. (8) are often cited as support
that PTCA before NCS is “safe.” But Elmore et al. (7) reviewed
only 14 patients who had PTCA before NCS, and Huber et al. (8)
studied only 50. Neither study is of sufficient size or design to
warrant conclusions regarding outcomes in patients who had
PTCA versus those who did not. Neither study examined timing
of PTCA and NCS.
Systemic autoimmune and inflammatory responses occur after
PTCA and stenting, with elevations in C-reactive protein, serum
amyloid type A, antinuclear factor and platelet adhesive molecule
expression (9–11). Changes persist up to three weeks following
PTCA (12). Activation of coagulation and fibrinolysis also occur
(13). Restimulation of the autoimmune, inflammatory, coagulation
and fibrinolytic systems during NCS may amplify both bleeding
and thrombotic complications when surgery occurs soon after
coronary intervention.
Several reports suggest that PTCA or stenting increases risks of
adverse cardiac outcomes for some patients who undergo subse-
quent NCS. Until we know more, prophylactic PTCA and
stenting prior to NCS should be undertaken with extreme caution
if surgery will occur within 90 days. Elective surgery should be
postponed whenever possible for a 40- to 90-day waiting period
after coronary intervention.
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